(Reuters) – Germany’s No. 2 drugmaker, Boehringer Ingelheim, on Friday appointed as chief executive Hubertus von Baumbach, a great-grandson of founder Albert Boehringer, putting a member of the family at the helm for the first time in 25 years.
Von Baumbach, 48, is currently Boehringer’s finance chief and will replace CEO Andreas Barner, 62, when he retires on June 30, 2016, the unlisted family-owned group said in a statement.
“Hubertus von Baumbach knows the corporation and its various divisions and his time on the Board of Managing Directors has prepared him well for the company’s future challenges,” shareholders’ committee chairman Christian Boehringer said.
“Along with colleagues on the Board of Managing Directors, he will continue the drive for change at Boehringer Ingelheim in order to secure the company’s independence in the long term,” he added.
After his retirement, Barner will join the shareholders’ committee, which is comparable to a corporate supervisory board. (Reporting by Patricia Weiss and Maria Sheahan; editing by Jason Neely)
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.
